Seasonal Variation in COPD Exacerbations: a Post-Hoc Analysis from the KRONOS Phase III Study of Budesonide/Glycopyrrolate/ Formoterol Fumarate Metered Dose Inhaler (BGF MDI)

被引：0
|
作者：
Rabe, K. F. [1 ,2 ]
Fabbri, L. M. [3 ]
Martinez, F. J. [4 ]
Ferguson, G. T. [5 ]
Bourne, E. [6 ]
Darken, P. [6 ]
DeAngelis, K. [6 ]
Aurivillius, M. [7 ]
Reisner, C. [7 ]
Dorinsky, P. [6 ]
机构：
[1] Lungenclin Grosshansdorf GmbH, Zentrum Pneumol & Thoraxchirurg, Grosshansdorf, Germany
[2] Deutsch Zentrum Lungenforsch Dzl, Airway Res Ctr North Arcn, Giessen, Germany
[3] Sahlgrens Univ Hosp, Gothenburg, Sweden
[4] Joan & Sanford I Weill Dept Med, New York, NY USA
[5] Pulm Res Inst Southeast Michigan, Farmington Hills, MI USA
[6] Pearl Astrazeneca, Durham, NC USA
[7] Astrazeneca, Cambridge, England
来源：
PNEUMOLOGIE | 2020年 / 74卷
关键词：
D O I：
10.1055/s-0039-3403160
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P488
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [1] Seasonal Variation in COPD Exacerbations: a Post-Hoc Analysis from the KRONOS Phase III Study of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI)
    Rabe, K. F.
    Fabbri, L. M.
    Martinez, F. J.
    Ferguson, G. T.
    Bourne, E.
    Darken, P.
    DeAngelis, K.
    Aurivillius, M.
    Reisner, C.
    Dorinsky, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [2] Rate of Severe COPD Exacerbations with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Dual Therapies: A Post-Hoc Analysis of the ETHOS Trial Excluding Data from China
    Ferguson, G. T.
    Rabe, K. F.
    Martinez, F. J.
    Wang, C.
    Trivedi, R.
    St Rose, E.
    Ballal, S.
    McLaren, J.
    Darken, P.
    Aurivillius, M.
    Dorinsky, P.
    Reisner, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [3] Analysis of exacerbation rates by time interval post-randomization in the KRONOS Phase III study of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI)
    Rabe, Klaus F.
    Fabbri, Leonardo M.
    Martinez, Fernando J.
    Ferguson, Gary T.
    Bourne, Eric
    Ballal, Sheila
    Darken, Patrick
    Deangelis, Kiernan
    Aurivillius, Magnus
    Reisner, Colin
    Dorinsky, Paul
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [4] Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS
    Chen Wang
    Ting Yang
    Jian Kang
    Rongchang Chen
    Li Zhao
    Huijie He
    Pryseley N. Assam
    Rong Su
    Eric Bourne
    Shaila Ballal
    Kiernan DeAngelis
    Paul Dorinsky
    Advances in Therapy, 2020, 37 : 1591 - 1607
  • [5] Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS
    Wang, Chen
    Yang, Ting
    Kang, Jian
    Chen, Rongchang
    Zhao, Li
    He, Huijie
    Assam, Pryseley N.
    Su, Rong
    Bourne, Eric
    Ballal, Shaila
    DeAngelis, Kiernan
    Dorinsky, Paul
    ADVANCES IN THERAPY, 2020, 37 (04) : 1591 - 1607
  • [6] Comparison of Inspiratory Capacity Assessed by Spirometry and Plethysmography: Post-Hoc Analysis of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) in Patients with COPD
    De Backer, W.
    De Backer, J.
    Darken, P.
    Jenkins, M.
    Martin, U. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [7] Single-Inhaler Triple Combination Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) at Two Corticosteroid Dose Levels in COPD: ETHOS Trial
    Rabe, K. F.
    Martinez, F. J.
    Ferguson, G. T.
    Wang, C.
    Singh, D.
    Wedzicha, J. A.
    Trivedi, R.
    St Rose, E.
    Ballal, S.
    McLaren, J.
    Darken, P.
    Aurivillius, M.
    Reisner, C.
    Dorinsky, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [8] Benefits of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) in Symptomatic Patients with COPD: A Post-Hoc Analysis from a Phase III, Randomized, Placebo-Controlled Study (PINNACLE-4)
    Lipworth, B. J.
    Collier, D. J.
    Feldman, G. J.
    Arora, S.
    Jenkins, M.
    Reisner, C.
    Martin, U. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [9] Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects
    Huang, Ying
    Assam, Pryseley Nkouibert
    Feng, Cong
    Su, Rong
    Dorinsky, Paul
    Gillen, Michael
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2020, 64
  • [10] RATE OF SEVERE COPD EXACERBATIONS WITH BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL FUMA-RATE DIHYDRATE METERED DOSE INHALER (BGF MDI) VERSUS DUAL THERAPIES: A POST-HOC SUBGROUP ANALYSIS OF THE ETHOS TRIAL
    Ferguson, G. T.
    Rabe, K. F.
    Martinez, F. J.
    Singh, D.
    Trivedi, R.
    Darken, P.
    Jenkins, M.
    Aurivillius, M.
    Dorinsky, P.
    THORAX, 2021, 76 : A16 - A16
12345